DNAprint Genomics (DNAG)

[worktoplay]

A little different twist in this article. I particularly liked this comment from Professor Lubbert:

http://www.icpeurope.net/services/document?id=BEP1_News_0000069114

"Forming such a close alliance with a US company is a significant milestone for Biofrontera," said Hermann Lübbert. "It provides us with substantial resources we need to move our products ahead in clinical development, and to establish the key clinical milestones which will form the basis of the future value of Biofronteral. We are excited by the recent progress in developing our lead product BF-Derm 1 for the treatment of severe chronic Urticaria, and the proceeds of this investment should enable us to bring this and other promising products to the market within the next three years.

"Improving the patient selection by DNAPrint's unique technology will render Biofrontera's clinical trials less costly and expedite the development of our drugs. We consider the ability to predict the individual patient's response to our drugs and extremely valuable addition to our effort in serving the patient's needs. Rapid success in drug development will move Biofrontera towards its goal of an initial public offering."

Later,
W2P